T 
Tianjin Pharmaceutical Da Ren Tang Group Corp 600329.SS · CNY
Health Care · Shanghai · 🇨🇳 China
41.77
-0.83%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥4.92bn
FY2016FY2025
Net income
CN¥2.13bn
FY2016FY2025
Free cash flow
CN¥342.5m
FY2016FY2025
Shareholders' equity
CN¥7.10bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥4.92bn | CN¥7.31bn | CN¥8.22bn | CN¥8.25bn | CN¥6.91bn | CN¥6.60bn | CN¥6.99bn | CN¥6.36bn | CN¥5.69bn | CN¥6.24bn |
| Research and development | CN¥189.8m | CN¥162.4m | CN¥184.6m | CN¥153.1m | CN¥161.1m | CN¥149.2m | CN¥133.4m | CN¥100.9m | CN¥79.4m | CN¥95.7m |
| Operating income | CN¥971.2m | CN¥774.0m | CN¥1.10bn | CN¥980.0m | CN¥866.7m | CN¥785.2m | CN¥759.0m | CN¥641.5m | CN¥331.0m | CN¥260.7m |
| Net income | CN¥2.13bn | CN¥2.23bn | CN¥986.7m | CN¥861.8m | CN¥769.1m | CN¥661.7m | CN¥625.6m | CN¥561.7m | CN¥476.1m | CN¥423.6m |
| Diluted earnings per share | 2.77 | 2.88 | 1.28 | 1.12 | 1.00 | 0.86 | 0.82 | 0.71 | 0.64 | 0.51 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥11.69bn | CN¥10.77bn | CN¥10.23bn | CN¥10.16bn | CN¥9.07bn | CN¥8.28bn | CN¥7.84bn | CN¥7.11bn | CN¥6.62bn | CN¥6.36bn |
| Cash and short-term investments | — | CN¥3.94bn | CN¥2.15bn | CN¥2.88bn | CN¥2.28bn | CN¥1.99bn | CN¥1.52bn | CN¥1.52bn | CN¥992.2m | CN¥1.15bn |
| Total liabilities | CN¥4.59bn | CN¥2.92bn | CN¥3.58bn | CN¥3.61bn | CN¥2.55bn | CN¥2.33bn | CN¥2.32bn | CN¥2.05bn | CN¥2.00bn | CN¥2.06bn |
| Debt | — | CN¥27.3m | CN¥325.6m | CN¥257.9m | CN¥33.2m | CN¥32.7m | CN¥33.7m | CN¥252.0m | CN¥262.0m | CN¥304.5m |
| Shareholders' equity | CN¥7.10bn | CN¥7.84bn | CN¥6.60bn | CN¥6.52bn | CN¥6.36bn | CN¥5.81bn | CN¥5.39bn | CN¥4.93bn | CN¥4.48bn | CN¥4.14bn |
| Shares outstanding | 770m | 773m | 769m | 769m | 768m | 767m | 767m | 795m | 745m | 824m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥461.1m | CN¥924.7m | CN¥688.5m | CN¥677.2m | CN¥852.4m | CN¥671.4m | CN¥495.5m | CN¥350.1m | −CN¥4.0m | CN¥419.9m |
| Capital spending | −CN¥118.6m | −CN¥117.8m | −CN¥140.9m | −CN¥107.9m | −CN¥156.9m | −CN¥189.2m | −CN¥205.6m | −CN¥175.8m | −CN¥114.4m | −CN¥116.2m |
| Free cash flow | CN¥342.5m | CN¥806.9m | CN¥547.6m | CN¥569.3m | CN¥695.5m | CN¥482.3m | CN¥289.9m | CN¥174.3m | −CN¥118.4m | CN¥303.7m |
| Dividends paid | −CN¥981.3m | −CN¥1.01bn | −CN¥859.1m | −CN¥386.7m | −CN¥232.0m | −CN¥231.8m | −CN¥169.2m | −CN¥164.7m | −CN¥127.5m | −CN¥205.5m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥939.4m | CN¥1.52bn | CN¥1.25bn | CN¥1.02bn | CN¥1.20bn | CN¥1.46bn | CN¥1.70bn | CN¥1.65bn |
| Operating income | CN¥252.2m | CN¥501.9m | CN¥89.3m | CN¥197.5m | CN¥1.83bn | CN¥438.8m | CN¥33.1m | CN¥148.2m |
| Net income | CN¥220.9m | CN¥423.8m | −CN¥21.2m | CN¥224.6m | CN¥1.55bn | CN¥374.2m | CN¥1.43bn | CN¥146.1m |
| Diluted earnings per share | 0.29 | 0.55 | -0.03 | 0.29 | 2.02 | 0.49 | 1.84 | 0.19 |
| Cash from operations | — | — | — | CN¥110.0m | CN¥132.0m | CN¥360.0m | CN¥357.0m | CN¥15.0m |
| Capital spending | −CN¥19.0m | −CN¥16.0m | −CN¥55.0m | −CN¥21.0m | −CN¥17.0m | −CN¥24.0m | −CN¥38.0m | −CN¥42.0m |
| Free cash flow | — | — | — | CN¥89.0m | CN¥115.0m | CN¥336.0m | CN¥319.0m | −CN¥27.0m |
| Total assets | CN¥10.53bn | CN¥10.44bn | CN¥11.69bn | CN¥11.59bn | CN¥12.85bn | CN¥11.17bn | CN¥10.77bn | CN¥10.97bn |
| Cash and short-term investments | — | — | — | CN¥1.73bn | CN¥3.63bn | CN¥1.48bn | CN¥3.94bn | CN¥1.45bn |
| Debt | — | — | — | CN¥16.6m | CN¥7.0m | CN¥72.4m | CN¥21.7m | CN¥1.24bn |
| Shareholders' equity | CN¥5.94bn | CN¥7.52bn | CN¥7.10bn | CN¥9.01bn | CN¥8.78bn | CN¥8.22bn | CN¥7.84bn | CN¥6.42bn |
Financial ratios
Data as of 22 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 19.7% | 10.6% | 13.3% | 11.9% | 12.5% | 11.9% | — | — |
| Net margin | 43.3% | 30.5% | 12.0% | 10.4% | 11.1% | 10.0% | — | — |
| Return on equity | 30.0% | 28.4% | 14.9% | 13.2% | 12.1% | 11.4% | — | — |
| Return on assets | 18.2% | 20.7% | 9.6% | 8.5% | 8.5% | 8.0% | — | — |
| Free cash flow yield | 2.1% | 3.8% | 3.1% | 2.9% | 3.7% | 3.2% | — | — |
| Revenue growth | -32.7% | -11.1% | -0.3% | 19.4% | 4.6% | -5.6% | — | — |
| Earnings growth | -4.4% | 125.9% | 14.5% | 12.0% | 16.2% | 5.8% | — | — |
| Current ratio | 1.59x | 2.35x | 2.03x | 2.17x | 2.64x | 2.59x | — | — |
| Debt to equity | — | 0.00x | 0.05x | 0.04x | — | 0.01x | 0.01x | 0.06x |
| Equity ratio | 60.7% | 72.8% | 64.5% | 64.2% | 70.2% | 70.1% | — | — |
| Interest coverage | 105.99x | 18.33x | 28.95x | 70.43x | 156.49x | 254.35x | — | — |
| R&D as a share of sales | 3.9% | 2.2% | 2.2% | 1.9% | 2.3% | 2.3% | — | — |
| Buybacks as a share of market value | 0.4% | -0.5% | 0.0% | -0.2% | -0.1% | 0.1% | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -15.8% | -5.7% | -3.6% |
| Operating income | -0.3% | 4.3% | 6.9% |
| Net income | 35.2% | 26.4% | 16.8% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 14.3% | 13.3% | 13.0% | 10.7% |
| Net margin | 35.7% | 21.6% | 18.1% | 13.6% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 16.5 | 10.7 | 26.2 | 26.0 | 31.4 | 20.3 | 17.0 | 17.6 | 23.3 | 34.0 |
| Price to sales | 7.1 | 3.3 | 3.1 | 2.7 | 3.5 | 2.0 | 1.5 | 1.6 | 1.9 | 2.3 |
Dividends and splits
Per share, in the currency the company pays
Paid for 15 years. Last went ex-dividend on 12 Feb 2026.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 3.73 | 1.28 | 1.12 | 0.50 | 0.30 | 0.30 | 0.22 | 0.20 |
- 2-for-1 split · 5 Jul 2010
- 1-to-1 reverse split · 19 Jul 2006
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.